Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Short-term Investments (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Short-term Investments readings, the most recent being $5.4 million for Q4 2025.

  • Quarterly Short-term Investments rose 57.43% to $5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.4 million through Dec 2025, up 57.43% year-over-year, with the annual reading at $5.4 million for FY2025, 57.43% up from the prior year.
  • Short-term Investments hit $5.4 million in Q4 2025 for Oramed Pharmaceuticals, up from $5.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $142.5 million in Q2 2023 and bottomed at $1.8 million in Q1 2023.
  • Average Short-term Investments over 5 years is $38.8 million, with a median of $12.1 million recorded in 2021.
  • Peak annual rise in Short-term Investments hit 4448.73% in 2024, while the deepest fall reached 98.75% in 2024.
  • Oramed Pharmaceuticals' Short-term Investments stood at $7.6 million in 2021, then crashed by 50.57% to $3.7 million in 2022, then soared by 1441.89% to $57.7 million in 2023, then plummeted by 94.04% to $3.4 million in 2024, then surged by 57.43% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Short-term Investments are $5.4 million (Q4 2025), $5.0 million (Q3 2025), and $22.9 million (Q2 2025).